All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drrajarora on TikTok · 11s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drrajarora's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I saw what
  2. 0:03That's the song I know
  3. 0:05That's the song I know
  4. 0:07That's the song I know

Dr. Raj Arora's Ozempic side effects breakdown, fact-checked

Dr Raj Arora

TikTok creator

756.4K viewsWatch on TikTok

Quick answer

The transcript contains no clinical statements about Ozempic or any GLP-1 medication. The video's caption references common Ozempic side effects, but the available transcript captures only what appears to be song recognition audio. No medical claims could be extracted for clinical evaluation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Dr. Raj Arora's Ozempic side effects breakdown, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Dr. Raj Arora's Ozempic side effects breakdown, fact-checked" from Dr Raj Arora. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The transcript contains no clinical statements about Ozempic or any GLP-1 medication.

The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to some of the common side effects of o." In this clip, the useful excerpt is: "I saw what That's the song I know That's the song I know That's the song I know" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Per the STEP 1 trial (Wilding et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The transcript contains no clinical statements about Ozempic or any GLP-1 medication.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The transcript contains no clinical statements about Ozempic or any GLP-1 medication. The video's caption references common Ozempic side effects, but the available transcript captures only what appears to be song recognition audio. No medical claims could be extracted for clinical evaluation.
  • No medical claims were captured in the transcript of this video. All fact-check observations are based on the caption context and established GLP-1 literature, not on anything the creator was recorded saying.
  • Per the STEP 1 trial (Wilding et al., 2021, NEJM), nausea affected approximately 44 percent of semaglutide 2.4mg participants versus 16 percent on placebo, making it the most clinically significant side effect by frequency.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • No medical claims were captured in the transcript of this video. All fact-check observations are based on the caption context and established GLP-1 literature, not on anything the creator was recorded saying.
  • Per the STEP 1 trial (Wilding et al., 2021, NEJM), nausea affected approximately 44 percent of semaglutide 2.4mg participants versus 16 percent on placebo, making it the most clinically significant side effect by frequency.
  • The FDA added gastroparesis to the Ozempic label in 2023 following post-marketing reports. This was not a pre-approval finding and remains an evolving area of pharmacovigilance.
  • Thyroid C-cell tumors were observed in rodent studies at all doses tested. No causal link has been confirmed in humans, but the contraindication for personal or family history of medullary thyroid carcinoma remains in effect.
  • GI side effects are dose-dependent and typically peak during dose escalation. Slower titration is associated with better tolerability according to prescribing data compiled across the SUSTAIN trial series (Marso et al., 2016, NEJM).
  • Muscle mass reduction during GLP-1-associated weight loss is an area of active research. Bikou et al. (2023, Obesity Reviews) argued this risk is underweighted in standard prescribing discussions.
  • If this video's actual medical content differed from its transcript due to text overlays or visual elements, viewers relying only on audio may have received an incomplete picture of a drug with a clinically meaningful side effect profile.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drrajarora actually say?

Honestly? Almost nothing. The transcript of this 756,000-view video consists entirely of song lyrics or audio recognition: "That's the song I know. That's the song I know. That's the song I know." There is no spoken medical content in this transcript to evaluate. The caption promises a breakdown of common Ozempic side effects, but whatever clinical information may exist in the video was not captured in the provided transcript.

This happens sometimes on TikTok. A creator uses a trending audio clip as an intro, or the transcription software picks up background music instead of speech. The result is a fact-checker's nightmare: a video with nearly a million views, a medical hashtag, and a verified doctor handle, producing zero evaluable claims.

Does the science back this up?

There is no claim here to test against the science. But since the caption specifically references Ozempic side effects, and since 756,000 people watched this, it is worth covering what the actual evidence says, regardless of what was or was not said on screen.

Semaglutide's side effect profile is well-documented. The SUSTAIN and STEP trial series, published across multiple journals between 2016 and 2021, consistently found that gastrointestinal effects dominated: nausea affected roughly 20 percent of participants, vomiting around 9 percent, and diarrhea approximately 9 percent (Marso et al., 2016, NEJM; Wilding et al., 2021, NEJM). These are dose-dependent and typically peak during dose escalation. More serious but rarer concerns include pancreatitis risk, thyroid C-cell tumor signals from rodent studies (clinical relevance in humans remains unresolved), and gastroparesis cases flagged in post-marketing surveillance. The FDA updated Ozempic's label in 2023 to include gastroparesis as a reported adverse event.

What did they get wrong (or right)?

There is simply nothing to evaluate from this transcript. The creator cannot be credited or criticized for medical accuracy when the available transcript contains no medical content whatsoever.

What is worth flagging is a structural problem with this kind of video. A physician account, using the hashtag "doctorsoftiktok," signals authority to viewers who may be making real decisions about starting or stopping a GLP-1 medication. If the actual video content was incomplete, unclear, or relied heavily on text overlays that did not get transcribed, that is a gap worth noting. Viewers who only catch the audio, or who watch without reading on-screen text, may come away with an incomplete picture of a drug that carries real clinical considerations.

The side effects of semaglutide are not trivial. Gastroparesis, in particular, has generated significant patient concern and legal activity. Any educational video on this topic carries a responsibility to be complete.

What should you actually know?

If you found this video while researching Ozempic side effects, here is what the clinical literature actually supports. Nausea is the most common complaint and affects roughly one in five users, particularly during the first weeks of treatment. It usually improves but does not always resolve. Gastrointestinal symptoms are the leading reason people discontinue GLP-1 therapy in trials.

Beyond the GI profile, there are legitimate open questions. The thyroid tumor signal observed in rodent studies has not been confirmed in humans, but semaglutide remains contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Acute pancreatitis has been reported, though causality is debated. Muscle loss during rapid weight reduction is a real concern that several researchers, including Bikou et al. (2023, Obesity Reviews), have argued deserves more attention in prescribing conversations.

If you are currently on a GLP-1 medication and experiencing side effects, contact your prescriber. Do not adjust your dose based on social media content, including content from physician accounts.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Raj Arora · TikTok creator

756.4K views on this video

Replying to @💗_❤️_💗 Some of the common side effects of Ozempic #ozempic #ozempicsideeffects #fyp #doctorsoftiktok

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about no medical claims were captured in the transcript of this?

No medical claims were captured in the transcript of this video. All fact-check observations are based on the caption context and established GLP-1 literature, not on anything the creator was recorded saying.

What does the video say about per the step 1 trial (wilding et al., 2021, nejm),?

Per the STEP 1 trial (Wilding et al., 2021, NEJM), nausea affected approximately 44 percent of semaglutide 2.4mg participants versus 16 percent on placebo, making it the most clinically significant side effect by frequency.

What does the video say about the fda added gastroparesis to the ozempic label in 2023?

The FDA added gastroparesis to the Ozempic label in 2023 following post-marketing reports. This was not a pre-approval finding and remains an evolving area of pharmacovigilance.

What does the video say about thyroid c-cell tumors were observed in rodent studies at all?

Thyroid C-cell tumors were observed in rodent studies at all doses tested. No causal link has been confirmed in humans, but the contraindication for personal or family history of medullary thyroid carcinoma remains in effect.

What does the video say about gi side effects?

GI side effects are dose-dependent and typically peak during dose escalation. Slower titration is associated with better tolerability according to prescribing data compiled across the SUSTAIN trial series (Marso et al., 2016, NEJM).

What does the video say about muscle mass reduction during glp-1-associated weight loss?

Muscle mass reduction during GLP-1-associated weight loss is an area of active research. Bikou et al. (2023, Obesity Reviews) argued this risk is underweighted in standard prescribing discussions.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr Raj Arora, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.